Eddie Martucci: Okay. Thanks.
Operator: Thank you. Your next question comes from Vikram Purohit, Morgan Stanley. Vikram, please go ahead.
Gus Paul: Hi everyone. Congrats on the quarter. This is Gus Paul, on for Vikram. We have one question. And the question is, what have been some of the key areas of user feedback on Endeavor? And what are the key product updates your team is currently working through based on the feedback that you have been receiving?
Eddie Martucci: Vikram, are you – does it matter? Are you referring to EndeavorOTC or EndeavorRx?
Gus Paul: EndeavorRx.
Eddie Martucci: Or is it general? EndeavorRx.
Gus Paul: I mean I guess – I mean let’s make it general then.
Eddie Martucci: Okay. Yes. No problem.
Matt Franklin: Yes. I just want to make sure I address your specific question. I mean I think in general, what we are hearing is an incredible unmet clinical need, right. I think we are seeing as you saw both products increase in demand, right. So, there is an unmet clinical need out there. From a clinician perspective, from a patient perspective, I think they also find comfort in the rigorous science and clinical data, right. The rigorous data that backs these products and also the engaging entertainment video game format, particularly in the pediatric market, we have seen continued progress with maintaining improvement over time as well, so…
Eddie Martucci: Yes, just to add on – this is Eddie. It’s a good question. We believe that things like continuing to add features that will – that people are asking for in terms of engagement, continuing to add data and tracking features. All of these are things that actually come up in our feedback and because we are in now two different markets and our volumes continue to grow, we are able to actually get a lot of volume of this feedback. And so in those areas, kind of engagement features and data and tracking, these are all areas that one, we have on roadmap and two, what’s really great about digital therapeutics is we have a lot of potential and latitude to add features directly to the product and release on a timely cadence. So, we definitely intend to have updates coming, as Matt said, near-term updates in OTC as well as updates in Rx aimed at these areas.
Matt Franklin: Yes. And then specifically in adult market, we are just getting started. So, we are actively in the process of optimizing that product for the specific adult users that we are engaged with. And excited, as Eddie mentioned, that we can – one of the unique advantages of our product is that it can be kind of evergreen and refreshed to continue that cadence of updates.
Gus Paul: Awesome. Thank you very much.
Matt Franklin: Thank you.
Operator: [Operator Instructions] Your next question comes from Rahul Rakhit, LifeSci Capital. Rahul, please go ahead.
Rahul Rakhit: Hey guys. Thanks for taking my questions. I know it’s pretty early, but I was just wondering if you see any kind of trends in the OTC product about where patients are kind of leaning in terms of subscriptions? Is it – are you seeing more patients going – opting for one-month or two-month subscriptions versus the full year? Any color here would be pretty helpful.
